COMMUNIQUÉS West-GlobeNewswire
-
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
28/07/2026 -
Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences
28/07/2026 -
Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call
28/07/2026 -
Grief goes global on screen as first-of-its-kind festival receives over 500 films from six continents
28/07/2026 -
Cato Healthcare Supply Strengthens Executive Leadership Team
28/07/2026 -
Dandy Partners with Yeshiva University's New College of Dental Medicine to Power the Future of Digital Dentistry Education
28/07/2026 -
Slate Medicines Establishes Clinical and Scientific Advisory Boards to Advance Next-Generation Migraine Prevention Therapeutics
28/07/2026 -
Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
28/07/2026 -
CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference
28/07/2026 -
Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship
28/07/2026 -
Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK
28/07/2026 -
Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial
28/07/2026 -
YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada
28/07/2026 -
Exagen Inc. to Participate in Upcoming Investor Conference
28/07/2026 -
Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
28/07/2026 -
Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides
28/07/2026 -
Claris Bio Unveils Development Strategy, Planned Pivotal Study Supported by $118 Million Series B Financing from Top-Tier Investors, and Multiple Leadership Appointments
28/07/2026 -
Oak Hill Bio Announces Dosing of First Participant in BEACON Phase 3 Clinical Trial of Rugonersen in Angelman Syndrome
28/07/2026 -
Daré Bioscience Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx
28/07/2026
Pages